RANI

Rani Therapeutics Holdings, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-26

Figures on this page computed 2026-11-08 12:48 UTC

Last close

0.57USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-26

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-13
The filing itself
-1817.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
-1151.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
0.13Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Margins is the furthest below its sector's middle: 0.04 against 0.23 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.68x

1.18x

0.57x

0.14x

0.10x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-26

Sales1.68x
Its own average over 7 years, 974.1K.
Profit1.18x
Its own average over 7 years, -25.1M.
Free cash flow0.57x
Its own average over 7 years, -33.1M.
Debt0.14x
Its own average over 7 years, 30.5M.
Price0.10x
Its own average over 6 years, 6. Market data, 2026-11-04

Price is furthest from its own average, at 0.10 times.

Sales is 1.68 times its own 7-year average; Profit is 1.18 times its own 7-year average; Free cash flow is 0.57 times its own 7-year average; Debt is 0.14 times its own 7-year average; Price is 0.10 times its own 6-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-26

Sales against its own 7-year average1.68
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
The filing itself
Profit against its own 7-year average1.18
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
The filing itself
Free cash flow against its own 7-year average0.57
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
The filing itself
Debt against its own 7-year average0.14
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-126417
Reported in
USD
The filing itself
Price against its own 6-year average0.10Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD